<DOC>
	<DOCNO>NCT00927875</DOCNO>
	<brief_summary>The purpose study determine maximum tolerate dose ( MTD ) BMS-833923 administer combination carboplatin etoposide follow BMS-833923 alone subject extensive-stage Small Cell Lung Cancer ( SCLC ) .</brief_summary>
	<brief_title>A Study BMS-833923 With Carboplatin Etoposide Followed BMS-833923 Alone Subjects With Extensive-Stage Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>Histologically cytologically confirm small cell lung cancer , without prior chemotherapy treatment Men Women least 18 year old Eastern Cooperative Oncology Group ( ECOG ) status 02 Significant cardiovascular disease Prior treatment small cell lung cancer permit , except palliative radiation limit field exclude chest ( e.g . painful metastasis ) . Symptomatic brain metastasis Women pregnant breastfeed Women childbearing potential ( WOCBP ) unwilling/unable use acceptable method avoid pregnancy Uncontrolled medical disorder active infection Concurrent therapy investigational product</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
</DOC>